Brain Metastases from breast cancer: Identification of a high-risk group

被引:121
作者
Evans, AJ [1 ]
James, JJ [1 ]
Cornford, EJ [1 ]
Chan, SY [1 ]
Burrell, HC [1 ]
Pinder, SE [1 ]
Gutteridge, E [1 ]
Robertson, JFR [1 ]
Hornbuckle, J [1 ]
Cheung, KL [1 ]
机构
[1] City Hosp, Nottingham Breast Inst, Nottingham NG5 1PB, England
关键词
brain metastasis; breast cancer; oestrogen receptor; screening;
D O I
10.1016/j.clon.2004.03.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Brain metastases from breast cancer are an uncommon initial presentation of metastatic breast cancer, but brain metastases commonly occur later in women's metastatic illness. The aims of this study were to document the type, frequency, and temporal occurrence of brain metastases from breast cancer as well as the survival of women with such metastases, and to attempt to identify a subgroup of women at high risk of brain metastases who may benefit from pre-emptive medical intervention. Materials and methods: The radiological reports of all women presenting with metastases aged under 70 years who had subsequently died were examined. The type, frequency, temporal occurrence and survival with brain metastases were documented. Correlations were sought between the frequency of brain metastases and age at metastatic presentation, tumour grade, histological type and oestrogen receptor (ER) status. Results: Of 219 patients who had died with metastatic disease and who were under 70 years of age at metastatic presentation, 49 (22%) developed brain metastases. The development of brain metastases was related to young age (P = 0.0002), with 43% of women under 40 years developing brain metastases. Brain metastases were more common in women whose tumours were ER negative (38%) compared with women with ER-positive disease (14%) (P = 0.0003). By combining age and ER status, it is possible to identify a group of women (age under 50 years and ER negative) with a 53% risk of developing brain metastases. This group included many women who had chemotherapy for visceral metastases, and 68% had either stable disease or disease response at other sites at the time of brain metastases presentation. Conclusion: It is possible to identify a subgroup of women with metastatic breast cancer at high risk of brain metastases who may benefit from pre-emptive medical intervention, such as screening or prophylactic treatment.
引用
收藏
页码:345 / 349
页数:5
相关论文
共 34 条
[1]  
Amendola BE, 2000, CANCER J, V6, P88
[2]   BRAIN METASTASES IN BREAST-CANCER - NATURAL-HISTORY, PROGNOSTIC FACTORS AND OUTCOME [J].
BOOGERD, W ;
VOS, VW ;
HART, AAM ;
BARIS, G .
JOURNAL OF NEURO-ONCOLOGY, 1993, 15 (02) :165-174
[3]  
BOOGERD W, 1992, CANCER, V69, P972, DOI 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO
[4]  
2-P
[5]   COMBINATION THERAPY WITH PLATINUM AND ETOPOSIDE OF BRAIN METASTASES FROM BREAST-CARCINOMA [J].
COCCONI, G ;
LOTTICI, R ;
BISAGNI, G ;
BACCHI, M ;
TONATO, M ;
PASSALACQUA, R ;
BONI, C ;
BELSANTI, V ;
BASSI, P .
CANCER INVESTIGATION, 1990, 8 (3-4) :327-334
[6]   High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel [J].
Crivellari, D ;
Pagani, O ;
Veronesi, A ;
Lombardi, D ;
Nolè, F ;
Thürlimann, B ;
Hess, D ;
Borner, M ;
Bauer, J ;
Martinelli, G ;
Graffeo, R ;
Sessa, C ;
Goldhirsch, A .
ANNALS OF ONCOLOGY, 2001, 12 (03) :353-356
[7]  
DAVIS PC, 1991, AM J NEURORADIOL, V12, P293
[8]   INFLUENCE OF AGE ON THE METASTATIC BEHAVIOR OF BREAST-CARCINOMA [J].
DELAMONTE, SM ;
HUTCHINS, GM ;
MOORE, GW .
HUMAN PATHOLOGY, 1988, 19 (05) :529-534
[9]  
DISTEFANO A, 1979, CANCER, V44, P1913, DOI 10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO
[10]  
2-D